Opinion|Videos|September 11, 2024
Central Precocious Puberty Treatment Starts, Discontinuations and Misconceptions
Experts address common misconceptions about the timing of central precocious puberty treatment initiation and discontinuation, highlighting research on outcomes for therapy started before age 7 and continued beyond age 12.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are common misconceptions regarding the timing of therapy initiation and discontinuation?
- What has research shown regarding outcomes for initiating therapy before age 7 years or discontinuing therapy after age 12 years?
- What consideration should clinicians give about the time to first menses after treatment cessation?
Advertisement
Related to this article
Nationwide Children's experts urge early screening and family-based lifestyle change as youth-onset T2D progresses faster than adult disease.
Glucommander Pediatrics received FDA Breakthrough Device Designation for IV insulin dosing in hospitalized children younger than 2 years, but remains uncleared.
ISPAD, EASD, and ADA urge pediatric diabetes teams to build center-specific transition policies, use readiness checklists, and ensure timely handoffs to adult clinicians.
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
Hand, foot, and mouth disease: Red flags pediatricians should know
2
Youth-onset type 2 diabetes may progress faster, signs easy to miss
3
FDA approval of Gazyva offers new option for pediatric INS
4
Infant skin care: Choosing products that protect the skin barrier
5